Publications by authors named "Hiroyuki Houzawa"
Introduction: Treatment satisfaction in patients with atopic dermatitis (AD) has been investigated in several studies, but the desire for alternative treatment options is unclear and has not been previously evaluated. We conducted a cross-sectional, web-based survey aimed at evaluating the desire for alternative treatment options in adults with AD from a patient registry in Japan.
Methods: Main eligibility criteria were adults aged ≥ 18 years with AD who were receiving treatment with topical corticosteroids (TCS) and not systemic therapy.
Article Synopsis
- * Among 2028 patients with anaplastic lymphoma kinase-positive non-small cell lung cancer, the incidence of crizotinib-related ILD was 5.77%, with specific risk factors such as age, performance status, and smoking history identified.
- * The findings suggest that crizotinib should be administered cautiously to patients with these risk factors and that close monitoring for ILD is essential due to the potential for severe cases.
Objective: This study was conducted to expand the sunitinib safety database in Japanese imatinib-resistant/-intolerant gastrointestinal stromal tumor patients. Retrospective analyses investigated common adverse events as potential prognostic markers.
Methods: Four hundred and seventy patients who received sunitinib between June 2008 and November 2009 were analyzed for safety, progression-free survival and overall survival; 386 for objective response rate; 88% received sunitinib on Schedule 4/2 starting at 50 mg/day.
Objective: This prospective, post-marketing study collected sunitinib safety and efficacy data in Japanese patients with unresectable/metastatic renal cell carcinoma. Retrospective analysis investigated adverse events as potential sunitinib efficacy biomarkers.
Methods: Patients administered sunitinib, after its release, were registered until reaching a pre-specified number of cases.